Under construction – not a live service
Sign in
Taking people in NetherlandsPhase 1

Imaging Test Tracer Study in Adults With Breast or Lung Cancer

Tests a radioactive imaging agent, Ga-DWJ155, in adults with advanced breast or lung cancer.

Plain-language title generated from the registry record
Registry title: A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

Key facts

Where
Groningen, NetherlandsSee the site
Phase
Phase 1

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced breast cancer (HR+/HER2- or HER2+) or advanced lung adenocarcinoma (a type of non-small cell lung cancer) who have a lesion that can be measured on a CT scan.

Age
18 to 100 years
Sex
All sexes
Disease stage
Advanced cancer that cannot be removed by surgery or has spread. Breast cancer: HR+/HER2- or HER2+. Lung cancer: NSCLC adenocarcinoma. At least one measurable lesion on a CT scan (RECIST v1.1).
Earlier treatment
HR+/HER2- breast cancer and lung cancer: untreated or currently on first-line systemic therapy. HER2+ breast cancer: untreated, or the cancer returned or did not respond after one or more lines of treatment.
Biomarker or test result
Breast cancer must be confirmed as HR+/HER2- or HER2+. Lung cancer must be confirmed as adenocarcinoma.

Main reasons for not taking part

  • Kidney function or blood test values outside the range set in the study protocol
  • Poor liver function
  • Urinary tract blockage that cannot be managed
  • Urinary incontinence that cannot be managed

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Source: NCT07117214, who can take part

Where in Netherlands

  • Groningen, Provincie GroningenHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Novartis Pharmaceuticals
Trial code
NCT07117214
Record updated
27 August 2026
Original description
This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative (HR+/HER2-) and HER2 positive (HER2+) advanced breast cancer (aBC) and advanced Non-Small Cell Lung Cancer (aNSCLC) adenocarcinoma.Read full original descriptionShow less

A Phase I, Open Label First in Human Study to Evaluate the Imaging Performance, Safety, Biodistribution and Pharmacokinetics of [68Ga]Ga-DWJ155 in Adult Patients With Advanced Breast Cancer and Advanced NSCLC

This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative (HR+/HER2-) and HER2 positive (HER2+) advanced breast cancer (aBC) and advanced Non-Small Cell Lung Cancer (aNSCLC) adenocarcinoma.

Inclusion: Age ≥ 18 years old; Patients with histologically or cytologically confirmed and documented HR+/HER2- advanced breast cancer (aBC), advanced defined as locoregionally advanced unresectable or metastatic, either untreated or currently receiving first line of systemic therapy OR patients with histologically or cytologically confirmed and documented HER2+ aBC, advanced defined as locoregionally advanced unresectable or metastatic, either untreated or relapsed/refractory (r/r) after one or more lines of treatment OR patients with histologically or cytologically confirmed and documented advanced NSCLC (aNSCLC) adenocarcinoma, advanced defined as locoregionally unresectable or metastatic, either untreated or currently receiving first line of systemic therapy; Presence of measurable disease (at least one target lesion) according to RECIST v1.1 assessed by conventional CT scan.

Exclusion: Patients having out of range laboratory values for kidney function and blood markers as defined in the study protocol; Patients with inadequate hepatic function; Unmanageable urinary tract obstruction or urinary incontinence; Other protocol-defined inclusion/exclusion criteria may apply.

ClinicalTrials.gov NCT07117214